Onabotulinumtoxin A for chronic migraine with medication overuse: clinical results and changes in catastrophising attitude. Preliminary data

Neurol Sci. 2018 Jun;39(Suppl 1):173-174. doi: 10.1007/s10072-018-3387-1.

Authors

Licia Grazzi¹, Eleonora Grignani², Emanuela Sansone³, Alberto Raggi², Matilde Leonardi², Domenico D'Amico³

Affiliations

¹ Headache and Neuroalgology Unit, Neurological Institute "C. Besta" IRCCS Foundation, Via Celoria 11, 20133, Milan, Italy. licia.grazzi@istituto-besta.it.
² Neurology, Public Health and Disability Unit, Neurological Institute "C. Besta" IRCCS Foundation, Milan, Italy.
³ Headache and Neuroalgology Unit, Neurological Institute "C. Besta" IRCCS Foundation, Via Celoria 11, 20133, Milan, Italy.

PMID: 29904878
DOI: 10.1007/s10072-018-3387-1

No abstract available

MeSH terms

Adult
Botulinum Toxins, Type A / therapeutic use*
Catastrophization / drug therapy*
Catastrophization / psychology
Chronic Disease / drug therapy
Disability Evaluation
Female
Headache Disorders, Secondary / drug therapy*
Headache Disorders, Secondary / psychology*
Humans
Male
Middle Aged
Neuromuscular Agents / therapeutic use*
Quality of Life
Time Factors
Treatment Outcome

Substances

Neuromuscular Agents
Botulinum Toxins, Type A